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NRAS mutant melanoma
Mohammad Atefi1, Bjoern Titz2, Earl Avramis1, Charles Ng5, Deborah JL Wong1, Amanda Lassen1, Michael Cerniglia1,
Helena Escuin-Ordinas1, David Foulad1, Begonya Comin-Anduix3,4, Thomas G Graeber2,4 and Antoni Ribas1,2,3,4,6*Abstract
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is
available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated
the possibility of blocking oncogenic signaling of NRAS by inhibiting two signaling points in the MAPK pathway.
Methods: Fourteen NRAS mutated human melanoma cell lines were treated with a pan-RAF inhibitor (PRi,
Amgen Compd A), a MEK inhibitor (MEKi, trametinib) or their combination and the effects on proliferation, cell
cycle progression, apoptosis, transcription profile and signaling of the cells were investigated.
Results: The majority of the cell lines showed a significant growth inhibition, with high levels of synergism of the
PRi and MEKi combination. Sensitive cell lines showed induction of apoptosis by the combination treatment and
there was a correlation between p-MEK levels and synergistic effect of the combination treatment. Proliferation of
sensitive cell lines was blocked by the inhibition of the MAPK pathway, which also blocked expression of cyclin D1.
However, in resistant cell lines, proliferation was blocked by combined inhibition of the MAPK pathway and cyclin
D3, which is not regulated by the MAPK pathway. Resistant cell lines also showed higher levels of p-GSK3β and less
perturbation of the apoptotic profile upon the treatment in comparison with the sensitive cell lines.
Conclusions: The combination of PRi + MEKi can be an effective regimen for blocking proliferation of NRAS
mutant melanomas when there is higher activity of the MAPK pathway and dependence of proliferation and
survival on this pathway.
Keywords: Melanoma, NRAS, MAPK, MEK inhibitor, pan-RAF inhibitor, Cyclin D3Introduction
Over activity of the RAS/RAF/MEK/ERK mitogen-
activated protein kinase (MAPK) pathway is the hall-
mark of the majority of melanomas, which is frequently
due to mutations in BRAF or NRAS in approximately 50%
and 20% of cases, respectively [1]. In melanomas with
BRAFV600 mutation, the MAPK pathway, and therefore
the growth of melanoma cells, can be efficiently blocked
by BRAF inhibitors such as vemurafenib or dabrafenib
[2,3]. However, no effective direct inhibitor of mutated
NRAS is available.* Correspondence: aribas@mednet.ucla.edu
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unless otherwise stated.In normal cells, RAS is the critical switch that connects
the signal of activated receptor tyrosine kinases (RTKs) to
the downstream signaling network particularly the MAPK
pathway. In the MAPK pathway, RAF isoforms (CRAF,
BRAF and ARAF) are the direct downstream proteins
of RAS [4]. Upon activation, homo or heterodimers of
RAF activate MEK1 and MEK2. The sole substrates of
MEKs are ERK1 and ERK2, which upon activation induce
activity of an array of pro-growth factors and inhibit
pro-apoptotic signals [5]. In most cells, MAPK signaling is
required for induction of cyclin D1 expression and there-
fore G1 to S phase cell cycle progression [6]. The MAPK
pathway activity also induces phosphorylation of the
pro-apoptotic protein BIM (BCL2L11), which targets
this protein for proteasome-mediated degradation [7].
Considering the significant role of the MAPK pathway,
feedback systems are in place to regulate its activity.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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upstream, while dual specificity phosphatases (DUSP4 and
DUSP6) dephosphorylate ERK1/2 [8].
In the case of mutated RAS, the main direct effector
protein is CRAF, which transfers the signal to the
downstream factors in the MAPK pathway. It has been
reported that CRAF also plays other roles independent
of the MAPK signaling and can regulate other effectors
such as MST-2 (MAP3K10) and ASK-1 (MAP3K5) [9].
There is also evidence that independent of the MAPK
pathway, CRAF signaling is directly involved in regulating
anti-apoptotic factors in mitochondria [10]. Despite the
central role of CRAF, the signal from the mutated NRAS
can be also transferred by BRAF to the downstream path-
way. Studies on xenografts of a NRAS mutant human
melanoma cell line indicated that shRNA knockdown of
both BRAF and CRAF caused delay in the tumor forma-
tion [11]. This data indicates that perhaps a pan-RAF
inhibitor (PRi) could successfully block transmission of
the oncogenic signal from mutated NRAS to the down-
stream protein MEK.
Immediately downstream of RAFs, MEK is one of the
main signaling nodes in the MAPK pathway and MEK
inhibitors have shown significant growth inhibitory effects
in some BRAF and NRAS mutant melanoma cells [12,13].
BRAF mutant cell lines usually show higher sensitivities,
at sub-nano molar levels, to the MEK inhibitors while
NRAS mutants are usually less sensitive to the inhibition
of this kinase [14]. In a clinical trial with one of the MEK
inhibitory drugs (MEK162) about 20% of patients with
NRAS mutated melanoma showed clinical responses with
a median progression free survival of 3.7 month [15].
However, the short duration of the response and pro-
gression free survival in these patients indicate that
combination therapy strategies are needed to be designed
for NRAS mutant melanomas. Considering the role of the
MAPK signaling in induction of cyclin D1, recently a
phase Ib/II clinical study with the combination of the
MEK inhibitor MEK162 and a CDK4/6 inhibitor (LEE011)
is being conducted (NCT01781572). Early clinical results
are supportive of a potential increased antitumor effect
achieved by combining a MEK inhibitor with a CDK4/6
inhibitor in patients with NRAS mutant melanoma [16].
In BRAF mutant melanomas, over-activity of alternative
pathways, such as PI3K/AKT, can induce resistance to
the inhibitors of the MAPK pathway [17]. Reasonably a
similar mechanism of resistance may exist in some of
the NRAS mutant melanomas and therefore treating
them with a combination of MEKi + PI3Ki may provide
beneficiary effects. Indeed, in a preclinical study, com-
bined inhibition of MEK and PI3K/AKT pathway provided
synergistic effects in NRAS mutant cells [18]. However,
clinical studies are needed to determine the effectiveness
of such regimens in patients.Previous studies have shown that one of the main
reasons for resistance to the targeted therapy approach
is the reactivation of the main oncogenic driver pathway
through the adjustment of feedback systems [19]. To
prevent the reactivation of an oncogenic pathway and to
achieve more effective inhibitory effects, the strategy of
combination therapy with two drugs that block a pathway
at two signaling points has been adopted. Along with
the same line of thought, the idea of combining a BRAF
inhibitor with a MEK inhibitor has been tested for the
treatment of BRAF mutated melanomas. Interestingly,
this regimen resulted in superior inhibitory effects and
reduced toxicities [20]. However, in the case of NRAS
mutant melanomas, due to the paradoxical activation of
the MAPK pathway, specific BRAF inhibitors cannot be
used. On the other hand, the paradoxical activation can
be avoided by using a PRi that blocks activities of both
BRAF and CRAF [21]. Moreover, to improve the growth
inhibitory effect of the PRi in NRAS mutant melanomas
and to block the feedback mechanisms that may reactivate
the MAPK pathway upon the treatment with a single drug,
a MEKi can be used in combination. This combination
treatment may also provide the possibility of decreasing the
dose of MEKi and therefore decreasing its toxicities.
In this study, we hypothesized that the oncogenic effects
of mutated NRAS could be inhibited by agents that block
proteins downstream of the MAPK pathway. However, to
avoid the feedback or paradoxical activation of the MAPK
pathway in NRAS mutated melanomas, the pathway was
blocked at both RAF and MEK steps by using the combin-
ation of a PRi (Amgen Compd A) and a MEKi (trametinib).
A panel of 14 human melanoma cell lines with various
NRAS mutations was used for this study to investigate the
growth inhibitory effect of this combination. Here, we
report that combination of PRi and MEKi shows synergis-
tic effects in the majority of NRAS mutated cell lines in
the panel. Cell lines with higher activity of MAPK pathway
were more sensitive to the combination therapy. The re-
sistance to therapy and lack of synergism was the result of
higher activity of pro-survival pathways and independence
of cell cycle progression from the MAPK pathway.
Results
Synergistic effect of PRi and MEKi combination in the
majority of NRAS mutant cell lines
Growth inhibition assays were performed with single
agent or a combination of PRi and MEKi on a panel of
14 NRAS mutant human melanoma cell lines (Table 1).
Among these cell lines, M249AR4 and M376 contain
both BRAFV600E and NRASQ61 mutations and are resistant
to single agent BRAF inhibitors, and the rest have
NRASQ61 mutations alone (Table 1). The responses of the
cell lines to single or combination treatment were variable
among the cell lines (Figure 1A & B). M243 was the most
Table 1 NRAS mutant cell lines and their characteristics
Cell line NRAS mutation Other known mutations
M202 NRASQ61L EGFR amplification
CDKN2A homozygous deletion
M207 NRASQ61L MITF amplification
EGFR L747_P753 > S
PTEN heterozygous deletion
M243 NRASQ61H homozygous PTENE156G heterozygous
CTNNB1_D32Y
M244 NRASQ61K heterozygous
M245 NRASQ61K heterozygous TP53R273H
M249AR4 NRASQ61K heterozygous MITF amplification
BRAFV600E heterozygous PTEN homozygous deletion
AKT2 amplification
M296 NRASQ61R heterozygous
M311 NRASQ61L homozygous
M318 NRASQ61L heterozygous PIK3CAC420R
M376 NRASQ61K heterozygous
BRAFV600E heterozygous
M408 NRASQ61K heterozygous
SBCL2 NRASQ61K homozygous
SKMEL173 NRASQ61K CTNNB1 D32G
CCND1 amplification
WM1366 NRASQ61L heterozygous
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ment (IC50 = 6pM). In all the cell lines, IC50 of MEKi was
lower than the IC50 of PRi. However, in some cell lines
(M202, M207, M311) the MEKi growth inhibition curves
showed a plateau after reaching the IC50 (Figure 1A).
These cell lines also showed low responses to PRi +MEKi
combination, particularly M311 which was the most
resistant cell line (IC50 > 100 nM) to this treatment. In the
resistant cell lines, upon reaching the plateau of growth
inhibition, at some concentration points the effect of com-
bination was slightly less than one drug alone. To identify
the synergistic effect of PRi and MEKi in the panel of cell
lines, Combination Indices (CI) at IC75 were calculated.
Based on the CI values, cell lines were divided into
three groups, six cell lines (such as M243, M296 and
SKMEL173) with high synergistic (CI ≤ 0.1) effects, six cell
lines with moderate synergistic effects (0.28 < CI < 0.39)
and cell lines with antagonistic effects (CI > 1.0) including
M207 and M311 (Figure 1C).
More pronounced effect of single agent or combination
treatment on cell cycle progression of sensitive NRAS
mutant cell lines
The effects of single agents or combination treatment on
cell cycle progression of three resistant (M202, M207,M311) and three sensitive cell lines (M243, M296,
SKMEL173) were investigated. Each cell line was treated
with PRi (500 nM), MEKi (25 nM) and their combination
for 48 hours. After harvest and fixation, cells were stained
with DAPI for cell cycle analysis by flow cytometry
(Figure 1D, Additional file 1: Figure S1). Overall, single
agents or combination treatment showed more prominent
effects on cell cycle progression of sensitive cell lines.
Treatment with PRi induced the G0/G1 phase by 50 to
80% in the sensitive cell lines and between 16 to 32% in
the resistant cell lines in comparison to their correspond-
ing control samples. MEKi-treated sensitive cell lines
showed between 16 to 21% of sub-G0 phase (an indication
of apoptosis), while among the MEKi-treated resistant cell
lines only one showed almost 8% of this phase. In sensitive
cell lines, addition of PRi to MEKi induced the sub-G0
phase even further, showing between 42 to 118% induction
in comparison with the MEKi single treatment (Figure 1D).
On the other hand, in the resistant cell lines the combin-
ation treatment did not cause any further significant
induction of sub-G0 phase in comparison with the MEKi
single treatment. These findings are in agreement with
the growth assay results indicating less drastic effects of
MAPK inhibitors particularly the combination treatment
on proliferation and survival of the resistant cell lines.
Effect of single and combination treatment on signaling
and feedback of the MAPK pathway in NRAS mutant
cell lines
Growth inhibition assays indicated that the cell lines in
the panel show variable responses to the treatments.
One possible reason for this variability among the cell lines
could be the result of differences in the activities of their
MAPK pathway either at the baseline or after treatment
with the drugs. To investigate such a possibility, NRAS
mutant cell lines were treated with single agent or combin-
ation of PRi and MEKi and analyzed by Western blotting
(Figure 2A, B and C). Regardless of the sensitivity or resist-
ance of the cell lines, PRi reduced the levels of p-MEK and
p-ERK. No paradoxical activation of the MAPK pathway
was observed in any of the cell lines at the concentration
range tested by us (Figure 2A, Additional file 2: Figure S2).
As it has been described before [12], MEKi treatment
caused induction of p-MEK, which was more pronounced
in the resistant cell lines, and reduction in p-ERK in all the
cell lines (Figure 2B). On the other hand, treatment with
the combination of PRi and MEKi subsided the p-MEK
inducing effect of MEKi as a single agent. Lack of p-MEK
induction in the cells treated with the combination can
be an indication for the interruption of the feedback or
compensatory mechanisms that are induced by MEKi
single agent treatment. In comparison with the single
agent treatment, combination of PRi +MEKi caused even
further decreases in p-ERK levels of all the cell lines to
Figure 1 Inhibitory effect of PRi and MEKi combination on cell growth of NRAS mutant melanoma cell lines, and effects of the
combination therapy on cell cycle progression. A) Four examples of growth inhibition assays performed on NRAS mutant melanoma cell
lines. M207 and M311 are examples of cell lines resistant to both drugs and their combination. M243 and M296 cell lines are examples of cell lines
with high synergistic effect of combination therapy. B) Bar graph of IC50s of PRi and MEKi alone or in combination. Cell lines were treated with serial
dilutions of the drugs starting from the highest concentration of 10000 nM for PRi and 1000 nM for MEKi. The ratio of PRi to MEKi concentration was
constant at 10:1. Cell lines are aligned in the graph according to their IC50s (in pM) of the combination treatment. C) Combination of PRi and MEKi
shows synergistic effects in most of the tested NRAS mutant cell lines. Combination Indices (CI) at IC75 were calculated by CalcuSyn software as
indicators of the synergistic effect of PRi and MEKi combination. Cell line are divided into three groups (intermittent lines), highly synergistic (CI≤ 0.1),
synergistic (0.28 < CI < 0.39) and antagonistic (CI > 1.0). D) Three resistant cell lines (M202, M207, M311) and three sensitive cell lines (M243, M296,
SKMEL173) were treated with PRi (500 nM), MEKi (25 nM) and their combination for 48 hours. After harvest and fixation, samples were stained with
DAPI for cell cycle analysis by flow cytometry. R = Resistant cell line, S = Sensitive cell line.
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combination is more effective for the complete block of
the MAPK pathway.
Correlation of p-MEK level with synergistic effect of
PRi + MEKi
The baseline activity of MAPK pathway was variable
among the tested cell lines. Some of the more sensitive cell
lines to the combination therapy showed higher basal levels
of p-MEK and p-ERK than the more resistant cell lines. To
investigate the association of baseline MAPK pathway
signaling with the sensitivity to the treatment, the baseline
levels of p-MEK for each cell lines was quantified by densi-
tometry of the Western blots, as it has been described inthe methods and materials section. After normalization and
ranking of the p-MEK levels (Figure 2D), by performing
Spearman’s Rank analysis, we found a significant inverse
correlation (ρ = −0.7, p = 0.02) between the ranking of p-
MEK levels and ranking of Combination Indices at IC75s
of combination treatment (Figure 2E, Additional file 3:
Figure S3, Additional file 4: Figure S4). This correlation
indicates that the cell lines with higher levels of p-MEK, or
higher activity of MAPK pathway, exhibit higher synergistic
effects with the combination treatment and vice versa.
These findings suggest that perhaps the higher level of
MAPK activity is an indication for the higher dependency
on this pathway and therefore higher sensitivity to the
complete blockade of this pathway.
Figure 2 Inhibitory effect of single agent and combination treatment on MAPK signaling and correlation of basal p-MEK level with the
synergistic effect of PRi and MEKi combination. A, B and C) Western blot analysis of NRAS mutant cell lines treated for 24 hours with DMSO,
or 500 nM of PRi (A) or 25 nM of MEKi (B) or combination of 500 nM of PRi and 25 nM of MEKi (C). The included heat maps were generated from
log2 of IC50s (from Figure 1B) to indicate the cell lines responses across all the treatments ranging from the most sensitive (green) to the most
resistant (red). D) Relative p-MEK levels of NRAS mutant cell lines were quantified from the intensity of untreated bands on Figure 2B. The reference
band (Ref.) is the untreated M207 that was used for the normalization of values between the blots. E) Reverse correlation (Spearman’s Rank analysis,
ρ = −0.7, p = 0.02) between the CI ranking (Figure 1C) and the ranking of p-MEK levels, indicating that the cell lines with higher levels of p-MEK exhibit
higher synergistic effects with the combination treatment.
Atefi et al. Molecular Cancer  (2015) 14:27 Page 5 of 12Expression profiling of resistant and sensitive cell lines
indicating similar MAPK, but distinct cell-cycle and
apoptosis response to the treatments
In order to better understand the mechanism of sensitivity
or resistance, we performed transcription microarray
analysis on M207 and M296 cell lines, which are repre-
sentative of the cell lines with no synergistic or highly
synergistic responses to combination treatment, respect-
ively. As we investigated the effect of the treatments on
the published signatures of MAPK-activation and MEK-
activation [8,22], we observed a similar pattern of down
regulation of these signatures in both cell lines (Figure 3A).
These results are in agreement with Western blot data
(Figure 2). Since in both cell lines the MAPK signature
was down regulated by the treatments, perhaps the resist-
ance of M207 is due to the lower dependency of this cell
line on MAPK pathway or the result of activities of path-
ways other than the MAPK.
One of the main differences between M207 and M296
was in the effect of treatments on the cell cycle expressionprofiles, which is in agreement with the phenotypes
observed in cell cycle analysis experiments (Figure 1D).
As it is indicated by the heat map and the bar graph in
figure 3B, blocking of MAPK pathway caused the overall
down regulation of cell cycle profile more prominently in
M296 than in M207. The down regulation of the cell cycle
profile was not confined to a particular phase of cell cycle.
In the sensitive cell line M296, in addition to cyclin D1,
that is involved in G1 to S phase progression, other factors
involved in the subsequent phases such as CDK1, CDK2,
cyclin A2 and cyclin B1 were also down regulated by the
treatments.
Moreover, in comparison with the resistant cell line
M207, the apoptosis response profile of M296 showed
higher perturbations with the treatment (Figure 3C). In
M296, higher perturbation of apoptotic profile by the
treatments, particularly the combination treatment, may
reflect an overall shift of balance from survival to apop-
tosis in this sensitive cell line. This is particularly more
evident through the lower expression of some anti-
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Figure 3 Expression profiles of M207 and M296 indicating a similar MAPK, but distinct cell-cycle and apoptosis response to the treatment.
A) Analysis of MAPK signaling by gene expression profiles of resistant cell line M207 and the sensitive cell line M296. B) The effect of treatments on
cell cycle expression profile of M207 and M296 are depicted by the heat map and the bar graph. C) Higher perturbation of apoptotic profile by the
treatments in the sensitive cell line M296 in comparison with M207. For these experiments cell lines were treated with DMSO, 25 nM of MEKi, 500 nM
of PRi or their combination for 24 hours before extraction of RNA for the microarray analysis.
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increase in expression of pro-apoptotic factors such as
BCL2L11 (BIM) in treated M296 cells. In this cell line,
this perturbation pattern is perhaps due to the direct or
indirect dependence of these factors expression on the
MAPK pathway. Considering the microarray results
regarding the cell cycle progression and apoptosis, we
sought to perform further experiments at protein and
cellular levels to investigate the role of important cell
cycle progression factors in sensitivity or resistance. More-
over, since apoptosis or survival is concerted through the
intricate balance of pro and anti-apoptotic factors at pro-
tein level, in the following experiments, we investigated
the presence of pro-survival signaling, effect of treatment
on BCL2L11 protein level and induction of apoptosis at
cellular level.
Lack of dependency of resistant cell lines on cyclin D1
and their dependency on cyclin D3 for their proliferation
The microarray analysis indicated an overall down regu-
lation of cell cycle profile upon treatment of the sensitive
cell line M296. One of the important factors in this pro-
file is cyclin D1, which interacts with CDK4/CDK6 and
regulates transition of cell cycle from G1 to S phase. It isknown that expression of cyclin D1 is regulated by activity
of the MAPK pathway [6]. Expectedly, expression of cyclin
D1 RNA showed drastic decreases in M296 treated with
the inhibitors of MAPK pathway (Figure 4A). However,
regardless of the presence or absence of the drugs, RNA
of cyclin D1 was not detected in the resistant cell line
M207 (Figure 4A). On the other hand, RNA expression
of another member of cyclin D family, cyclin D3, was
detected in both cell lines. It is been suggested that the
expression of cyclin D3 is not directly regulated by the
activity of MAPK pathway [23]. Accordingly, expression
of cyclin D3 was not affected by the MAPK inhibitors
in M207, however treated M296 samples showed some
reduction. No RNA expression of cyclin D2 was detected
in either cell lines.
These findings were further investigated at the protein
level by Western blot analysis in three resistant (M202,
M207, M311) and three sensitive (M243, M296, MSK
MEL173) cell lines. No band for cyclin D1 was detected
in M202 and 207 confirming the RNA expression data
(Figure 4A, B and not shown RNA sequencing data). In
other cell lines, including the resistant cell line M311,
expression of cyclin D1 was down regulated by the inhi-
bitors of the MAPK pathway, particularly by the
Figure 4 Negative growth in resistant cell lines upon knockdown of cyclin D3 and blockade of the MAPK pathway. A) Bar graphs of cyclin D1
and cyclin D3 RNA expression in M207 and M296 cell lines determined by transcription microarray analysis as it was described before. Different colors on
the bars are the representation of signals from different probes for the same gene. B) Western blot analysis of cyclin D1 and D3 expressions in three
resistant (M202, M207, M311) and three sensitive (M243, M296, MSKMEL173) cell lines treated for 24 hours with 500 nM of PRi, 25 nM of MEKi or their
combination for 24 hours. C) Western blot analysis indicating successful blockade of cyclin D3 expression 72 hours after the transfection of the cells with
a cyclin D3 specific siRNA pool. D) Effect of cyclin D3 knockdown on growth of resistant and sensitive cell line. In this experiment, kinetics of growth was
monitored and recorded by an InCucyteZOOM device during a period of 110 hours. In the resistant cell lines (upper panel), negative growth was
achieved by the combination of cyclin D3 knockdown + PRi +MEKi. All the conditions were in triplicates and the assay was repeated twice.
Atefi et al. Molecular Cancer  (2015) 14:27 Page 7 of 12combination of the drugs (Figure 4B). Cyclin D3 protein
was detected in all the cell lines and the resistant cell
line M202 showed the highest expression of this pro-
tein. Levels of this protein were not affected by the
MAPK inhibitors except a very slight decrease in M296
cell line.
Considering these findings, we hypothesized that the
proliferation of resistant cell lines is perhaps dependent
on cyclin D3 and therefore to some extend should be
independent of MAPK pathway. To test this hypothesis,
expression of cyclin D3 was successfully blocked by a
cyclin D3-specific siRNA pool (sicyclin D3) in all the six
tested cell lines (Figure 4C). The proliferation kinetics
upon the knockdown of cyclin D3 in the presence and
absence of complete blockade of the MAPK pathway by
PRi +MEKi treatment was monitored and recorded by
automated imaging analysis (Figure 4D). In the resistantcell lines M202, M207 and M311 (Figure 4D upper
panel), negative growth rates were achieved only by the
treatment with the combination of sicyclin D3 + PRi +
MEKi, which reflects their proliferation dependency on
cyclin D3. This includes M311 cell line that despite its
high baseline expression of cyclin D1, and unlike the
sensitive cell lines, requires the combination of cyclin
D3 knockdown and blocking of the MAPK pathway
(which also blocks cyclin D1 expression) to show negative
growth rate. On the other hand, the sensitive cell lines
(lower panel) showed negative growth by the combination
of PRi +MEKi regardless of the cyclin D3 knockdown.
Overall, these data indicate that one of the mechanisms of
resistance is the dependency of the resistant cell lines on
cyclin D3, which is not mainly regulated by MAPK path-
way and cannot be down regulated by the inhibitors of
this pathway.
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lower apoptotic response of resistant cell lines to the
inhibition of MAPK pathway
In order to identify the signaling mechanism of resistance
to the combination treatment, we performed antibody
array analysis in the resistant cell line M207 and the
sensitive cell line M296 (Figure 5A, Additional file 5:
Figure S5). In agreement with the previous Western blot-
ting assays, the antibody array also showed that at the
baseline level, ERK proteins were less phosphorylated in
M207 than M296.
Based on the antibody array results, the most promin-
ent differences between these two cell lines, particularly
after the treatment with PRi +MEKi, were the higher
levels of pro-growth and pro-survival factors, such as p-
GSK3β and p-AKT in the M207 cell line (Figure 5A).Figure 5 High endogenous activity of pro-survival signaling and low
pathway. A) Higher levels of p-GSK3β and p-AKT in the resistant cell line M2
and the sensitive cell line M296 were treated with the solvent, PRi, MEKi or th
used as the reference (indicated as the value of 100) for all other samples. B)
not in M207 determined by transcription microarray analysis. Different colors
same gene. C) Western blot analysis of three resistant cell lines (M202, M207,
higher levels of p-GSK3B in the resistant cell lines and higher fold induction o
apoptotic response of the sensitive cell lines to the combination treatment de
PRi (500 nM), MEKi (25 nM) or the combination for 48 hours before the harveAntibody array also indicated a consistent and further
decrease in p-GSK3β upon treatment of the sensitive cell
line M296. Contrary to this finding in the M207 cell line,
as it was shown before by the transcription microarray, the
treatments caused higher perturbation of the pro-apoptotic
profile in M296 (Figure 2C). Of note, RNA expression of
the pro-apoptotic gene BCL2L11 (BIM) was induced by the
MAPK inhibitors, particularly the combination treatment,
in M296 but not in M207 cell line (Figure 5B).
To confirm these findings, we investigated levels of p-
GSK3β, BIM and p-AKT in representative resistant and
sensitive cell lines (Figure 5C). Interestingly, we identified
two patterns that distinguished the resistant cell lines
(M202, M207, M311) from the sensitive ones (M243,
M296, SKMEL173). First, p-GSK3β levels were higher in
the resistant cell lines in comparison to the sensitive lines.apoptotic response of resistant cell lines to the blockade of MAPK
07, determined by antibody array analysis of 24 phosphoproteins. M207
eir combination for 24 hours. The signal from solvent treated M296 was
Induction of BIM RNA expression by the MAPK inhibitors, in the M296 but
on the bars are the representation of signals from different probes for the
M311) and three sensitive cell lines (M243, M296, SKMEL173) indicating
f BIM in sensitive cell line upon the treatments for 24 hours. D) Higher
termined by cleaved PARP flow cytometry assay. Cells were treated with
st, fixation and antibody staining.
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lower in the sensitive cell lines, blocking of MAPK
pathway caused significant induction of this protein in
comparison with the basal BIM levels. In the resistant cell
lines, relative to the BIM basal levels, expression of this
protein was either not induced by the treatment or the
relative induction was not to the same magnitude ob-
served in the sensitive cell lines. Although p-AKT was
higher in the resistant cell line M207, we did not find a
distinguish pattern of AKT phosphorylation among the
rest of cell lines.
All these results referred to the higher levels of pro-
survival factors and less perturbations of pro-apoptotic
factors in the resistant cell lines. Indeed, as we investi-
gated the effects of PRi and MEKi on induction of apop-
tosis in the sensitive cell lines versus the resistant ones,
the results indicated that the combination treatment, for
48 hours, caused higher levels of cleaved PARP (20% to
46%) in the sensitive cell line (Figure 5D). Moreover, in
the sensitive cell lines addition of PRi to MEKi enhanced
the apoptotic effect of MEKi alone by 1.4 to 2.9 fold. On
the contrary, in the resistant cell lines treatments with
the same drugs induced less than 11% apoptosis. Overall,
these results provide strong evidence for the presence of
pro-survival and anti-apoptotic signaling in the resistant
cell lines which play important roles in diminishing the
effect of complete blockade of the MAPK pathway by
the combination treatment.
Discussion
NRAS mutation is detected in around 20% of melano-
mas; however no effective direct inhibitor of mutated
NRAS is clinically available [1]. The MAPK pathway is
one of the most important pathways downstream of
mutated RAS [4]. Therefore, we investigated the effect
of inhibiting the MAPK pathway as an alternative way of
blocking oncogenic signaling of mutated NRAS. It is
necessary to consider that: i) RAS mutants are less sensi-
tive to the MEK inhibitors in comparison to the BRAF
mutant melanomas [14]; ii) NRAS mutants exhibit para-
doxical activation of the MAPK pathway upon the treat-
ment with the BRAF inhibitors such as vemurafenib [21];
and iii) there is possibility of reactivation of the pathway
trough the adjustment of feedback systems. Our strategy
for avoiding or minimizing these issues was to block the
MAPK pathway at two signaling points by using the com-
bination of a RAF inhibitor, which blocks CRAF and
BRAF simultaneously and prevents paradoxical activation,
with a potent MEKi. Indeed, in this study the use of the
PRi in combination with the MEKi provided a complete
shutdown of the MAPK pathway in all the tested cell lines.
The majority of the cell lines showed a significant growth
inhibition and high levels of synergism of these two
drugs. However, despite the complete blockade of MAPKpathway signaling, some cell lines showed resistance to
single agent and the combination of the drugs, and exhib-
ited low or lack of synergism.
Interestingly, we found a variable baseline activity of
MAPK pathway among the cell lines in the NRAS mutant
panel. Sensitive cell lines showed higher level of p-MEK
and p-ERK as opposed to the more resistant cell lines that
had lower baseline levels of these two phosphoproteins.
Indeed, we found a significant correlation between the
ranking of p-MEK levels and the synergistic effect of
complete blocking of the MAPK pathway by the combin-
ation treatment. These findings suggest that perhaps
higher activity of the MAPK pathway is an indication for
higher dependency of the cells on this pathway and there-
fore higher sensitivity of these cell lines to the blockade of
the MAPK pathway.
In addition, upon performing cell cycle analysis and
apoptosis assays we observed a distinguished pattern of
response to the drugs in sensitive cell lines versus the
response of resistant cell lines. In most of the cells, pro-
gression from G0/G1 to S phase is regulated by the inter-
action of one of the cyclin D isoforms with CDK4/CDK6.
Indeed the effect of the MAPK pathway on induction of
cell cycle progression is mainly through the induction of
cyclin D1 expression [6]. Interestingly in two of the resist-
ant cell lines we did not detect expression of cyclin D1
and the only expressed isoform was cyclin D3. Expression
of cyclin D3 is believed to be independent of the MAPK
pathway activity [23]. Considering these results, we tested
the hypothesis that the cell cycle progression of resistant
cell lines is dependent on cyclin D3 and therefore is inde-
pendent of MAPK pathway signaling. Indeed, by a com-
bination of siRNA to cyclin D3 + PRi +MEKi, we achieved
a negative growth in the three tested resistant cell lines
while in the sensitive cell lines combination of PRi +MEKi
was sufficient to induce negative growth rate. Therefore,
we concluded that one of the main mechanisms of resist-
ance to this combination is the dependency of cell cycle
progression on cyclin D3, which is not regulated by the
MAPK and hence cannot be blocked by the inhibitors of
this pathway.
Both cyclin D1 and D3 can bind to CDK4/6 to induce
cell cycle progression from G1 to S phase. To block the
function of these cyclin-CDK complexes, inhibitors of
CDK4/6 have been developed. While in theory these
inhibitory compounds should be effective in cancer cells
that are dependent on either one of the cyclin Ds (cyclin
D1, D2 or D3), it is not clear if in practice they show
such a general effect. For instance, in an in vitro study
on breast cancer cell lines, the sensitivity to the CDK4/6
inhibitor palbociclib (PD 0332991) was mainly limited to
the luminal cell lines with a microarray signature of high
cyclin D1, high RB and low CDKN2A; meanwhile cyclin
D3 was not part of the sensitivity signature [24]. In the
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clinical study with the combination of the MEK inhibitor
MEK162 and a CDK4/6 inhibitor (LEE011) is being
conducted (NCT01781572). Early clinical results are sup-
portive of a potential increased antitumor effect achieved
by combining a MEK inhibitor with a CDK4/6 inhibitor in
patients with NRAS mutant melanoma [16].
In addition to the cell cycle progression, our results
also indicated that resistant cell lines are better equipped
to support their survival independent of the MAPK
pathway. The role of GSK3β in regulation of different
cell functions including metabolism, cell cycle progression
and cell survival has been very well studied. Phosphor-
ylation of GSK3β inhibits its activity and promotes cell
proliferation and survival [25]. Interestingly, in our study
one of the main differences between the resistant and
sensitive cell lines was the higher levels of p-GSK3β in
the resistant cell lines. Moreover, inhibition of the MAPK
showed no significant effect on the level of this phospho-
protein in the Western blot analysis of the resistant cell
lines.
Usually, p-GSK3β is considered to be downstream the
PI3K/AKT pathway. In this study, although higher levels
of p-GSK3β were detected in all three resistant NRAS
mutant cell lines, high levels of p-AKT was not detected
in two of them (Figure 5C). In these PRi +MEKi resistant
cell lines, presence of such pro-survival factor independ-
ent of AKT, and the cyclin D3 dependent proliferation,
may argue for a the possibility of a concomitant resistance
to the inhibitors of PI3K/AKT pathway as well. Although
in some studies on NRAS mutant cells, synergistic effect
of combining MEKi and inhibitors of PI3K/AKT have
been observed [18], further pre-clinical and clinical studies
are required to determine the effectiveness of such combi-
nations in the resistant cases.
One of the pro-survival effects of ERK is exerted through
the phosphorylation of the pro-apoptotic protein BIM and
therefore targeting this protein for degradation. Interest-
ingly, in comparison with the basal BIM levels, blockade of
MAPK pathway caused relatively higher fold inductions of
BIM protein in the sensitive cell lines. This is an indication
for the higher perturbation of pro-apoptotic factors and
the shift of balance toward apoptosis upon the blockade of
the MAPK pathway in the sensitive cell lines. Indeed, in
transcriptome studies, we observed the high perturbation
in the pro- apoptotic profile of treated sensitive cell line,
M296. As it was expected, by performing cleaved PARP
apoptosis assays, we observed higher rates of apoptosis in
PRi +MEKi treated sensitive cell lines as compare with the
resistant ones.
As it has been shown in BRAF mutant melanomas,
resistance to blocking of the MAPK pathway can be the
result of reactivation of the same pathway or activation
of alternative pathways. Reasonably the same pattern ofendogenous or developing resistance can exist in NRAS
mutant melanomas. In this study, we observed the syn-
ergistic effect of PRi +MEKi combination in majority of
NRAS mutant cell lines particularly in those with higher
activity of the MAPK, but not in cell lines with MAPK
independent pro-survival and cell cycle progression factors.
In the future preclinical and clinical studies, it would be
interesting to find out whether this combination shows
better outcomes and delays the onset of resistance in
comparison to single agent MEKi.
Conclusion
Considering the findings of this study, our general conclu-
sion is that level of basal p-MEK in each cell line reflects
the activity and importance of the MAPK pathway in the
cells. Perhaps, cell lines with higher levels of p-MEK are
also more dependent on this pathway and more sensitive
to the blockade of this pathway and its consequences such
as down regulation of pro-survival and cell cycle progres-
sion factors such as cyclin D1. On the other hand, cell
lines with lower activities of the MAPK pathway, that
contain higher activities of other pro-survival pathways
such as high p-GSK3β and dependency on cyclin D3 for
cell cycle progression are resistant to the blockade of the
MAPK pathway by the combination treatment.
Materials and methods
Reagents and cell lines
Trametinib was purchased from Selleck Chemicals
(Houston, TX) and the pan-RAF inhibitor (Amgen
Compd A - hereafter PRi) [26] was obtained from Amgen
(Thousand Oaks, CA) under a materials transfer agree-
ment (MTA). Human melanoma cell lines (M series) were
established from patient’s biopsies under UCLA IRB
approval # 11–003254. WM1366, SKMEL173 and SBCL2
cell lines were obtained from the American Type Culture
Collection (ATCC, Rockville, MD). Cells were maintained
and tested for mycoplasma as described before [17].
Presence of mutations in the genes of interest was checked
by OncoMap 3 or Iontrone, and was confirmed by PCR
and Sanger sequencing.
Cell proliferation and viability assays
Melanoma cell lines were treated with serial dilutions of
trametinib, PRi, their combinations or DMSO for 72 hours
or 5 days depending on the growth rate of the cell lines.
The assays were performed in duplicates for each concen-
tration and repeated at least twice. Cell viability was
detected by a bioluminescence assay (Promega, Madison,
WI). The IC50s were calculated from the growth inhib-
ition assays. To determine synergistic effect of the drugs,
Combination Index (CI) was calculated by CalcuSyn soft-
ware (version 2.0 Biosoft, Cambridge, UK).
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Cell lines were transfected with the cyclin D3 specific or
no target siRNAs (Dharmacon, Lafayette, CO), as it has
been described before [17] and were cultured in 96 well
plates. After 24 hours the cells were treated with DMSO
or PRi (500 nM) + trametinib (25 nM) combination. The
growth rate in each well was continuously monitored and
recorded by IncuCyteZoom instrument (Essen BioScience,
Ann Arbor, MI) in a period of 110 hours. Each assay was
performed in triplicate and repeated at least twice.
Western blotting and quantification of signal intensities
Western blotting was performed as previously described
[17]. Primary antibodies included p-AKT Ser473, AKT,
p-ERK Thr204/205, ERK, p-MEK Ser217/221, MEK, cyclin
D1, cyclin D3, p-GSK3β, GSK3β, BIM and GAPDH (all
from Cell Signaling Technology, Danvers, MA). The
immunoreactivity was revealed by use of an ECL2 kit
(Pierce Rockford, IL) and scanning of the blots by the
Typhoon scanner (Amersham Biosciences Co, Piscataway,
NJ). The intensity of the p-MEK bands were determined by
the ImageQuant software and were normalized between
the two blots by considering the reference sample (one
of the samples of the first blot duplicated on the 2nd
blot). The relative level of p-MEK for each sample was
determined by the ratio of each sample over the average
intensity of all the samples.
Cell cycle analysis and apoptosis
Cell lines were treated with DMSO or 500 nM PRi, 25 nM
of MEKi or their combinations for 48 hours. After the
harvest, cell cycle analysis was performed as it was
described before [12]. For analysis of apoptosis, cells
were treated, harvested, fixed and prepared similar to the
cell cycle analysis and then stained for detection of cleaved
poly [ADP-ribose] polymerase (PARP) by anti–PARP-
Alexafluor700 (clone F21-852; BD Biosciences). All flow
cytometry experiments were performed on LSRII (BD
Biosciences) flow cytometry machine [27].
Transcription microarray analysis
M207 and M296 cells were treated for 24 hours with
500 nM PRi, 25 nM of MEKi, or their combination. After
harvest total RNA was isolated by RNeasy kit (Qiagen,
Valencia, CA). Further processing, hybridization (Affyme-
trix Human U133plus2.0 Array), and slide scanning were
performed by the Clinical Microarray Core at UCLA. The
data was processed with R/Bioconductor [28] and samples
were RMA normalized. To calculate the MAPK-activation
and MEK-activation signature responses the respective
gene sets were obtained from Pratilas et al. [8] and Dry
et al. [22]. The expression data was log-transformed, cen-
tered, and scaled. The gene expression of the signature
genes was summarized as their median expression value.The cell-cycle and apoptosis gene sets were obtained from
the Reactome database (“REACTOME_CELL_CYCLE”,
“REACTOME_APOPTOSIS”). The expression data for the
subsets was filtered for a two-fold up- or down-regulation
in either cell line (combination treatment vs. control). For
the heat map visualization the data was log-transformed
and scaled. The overall effects of the treatments for cell-
cycle and apoptosis gene sets were determined using log-
transformed data, and the difference of expression between
the treated and untreated samples was calculated for each
cell line. Multiple probes for each gene were collapsed to
their average. The positive (or negative) perturbation score
(bar graph) was calculated as the sum of the positive (or
negative) relative expression values divided by the total
number of genes in the expression gene set.
Human Phospho-MAPK array analysis
Detection of a panel of phosphoproteins in M207 and
M296 was carried out by treating them with DMSO or
PRi (500 nM), MEKi (25 nM) or combination of the drugs
for 24 hours and using Human Phospho-Kinase Array Kit
(R&D Systems, Inc., Minneapolis, MN). Harvest of cells,
lysis and all other steps were performed according to
the instruction of the manufacturer. To detect the sig-
nal levels, arrays were exposed to ECL2 reagent (Pierce
Rockford, IL), scanned and signals were quantified as it
was described in the Western blotting in above. The
signals were normalized between the arrays by consid-
ering the reference spots. The relative signal level for
each phosphoprotein was determined by calculating the
ratio of each signal over the signal of M296 control
which was assigned the value of 100.
Additional files
Additional file 1: Figure S1. Flow cytometry histograms of cell cycle
analysis of 3 resistant and 3 sensitive cell lines treated for 48 hours with PRi,
MEKi or their combination indicating a significant induction of sub-G0 phase
in the sensitive cell lines upon the treatment with combination of PRi + MEKi.
Additional file 2: Figure S2. Inhibitory effect of different concentrations
of PRi, single dose MEKi and PRi + MEKi on activity of the MAPK pathway
signaling. Cells were treated for 24 hours with the mentioned conditions.
Additional file 3: Figure S3. CI75 and p-MEK level correlation plot in
NRAS mutated cell lines (Spearman’s rank correlation analysis and Pearson’s
product moment correlation). Ranking of CI75 of PRi + MEKi shows an
inverse correlation with the ranking of p-MEK levels.
Additional file 4: Figure S4. IC50 and p-MEK level correlation plots in
NRAS mutated cell lines (Spearman’s rank correlation analysis). Ranking of
IC50s of PRi + MEKi shows an inverse correlation with the ranking of p-MEK
levels. A) Correlation plot of ranking of PRi IC50s and ranking of p-MEK
levels. B) Correlation plot of ranking of MEKi IC50s and ranking of p-MEK
levels. C) Correlation plot of ranking of PRi + MEKi IC50s and ranking of
p-MEK levels.
Additional file 5: Figure S5. Human Phospho-MAPK Array for detection
of 24 phosphoproteins performed on melanoma cell lines. A) Differences
in signaling of the resistant and sensitive cell lines M207 and M296 were
investigated after treatment of these cell lines with the solvent, PRi
(500 nM), MEKi (25 nM) and their combination for 24 hours. For this
Atefi et al. Molecular Cancer  (2015) 14:27 Page 12 of 12purpose the antibody array from R & D Systems was used which detects
24 phosphoproteins in duplicates. Each spot represent one phosphoprotein.
The signals from the Reference spots were used for the normalization
among the arrays. B) Map of the phosphoprotein spots on the array
adopted from R & D systems website.
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